Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients?

Annals of Oncology

Volumn 19, Issue 7, 2008, Pages 1284-1287

  Suzuki, S ^a   Kajiyama, H ^a   Shibata, K ^a   Ino, K ^a   Nawa, A ^a   Sakakibara, K ^b   Matsuzawa, K ^c   Takeda, A ^d   Kinoshita, Y ^e   Kawai, M ^f   Nagasaka, T ^g   Kikkawa, F ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Okazaki City Hospital   (Japan)

^c ANJO KOSEI HOSPITAL   (Japan)

^d GIFU PREFECTURAL TAJIMI HOSPITAL   (Japan)

^e OGAKI MUNICIPAL HOSPITAL   (Japan)

^f TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^g NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Clear cell carcinoma of the ovary (CCC); Epithelial ovarian carcinoma (EOC); Lymphadenectomy; Stage; Survival

Indexed keywords

BLEOMYCIN; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; VINBLASTINE;

ADULT; AGE; AGED; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; HYSTERECTOMY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; SURVIVAL RATE; SYSTEMIC RETROPERITONEAL LYMPHADENECTOMY; UNIVARIATE ANALYSIS;

EID: 46249099390     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn059     Document Type: Article

References (12)

1. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-2589.
2. Kennedy AW, Biscotti CV, Hart WR et al. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989; 32: 342-349.
3. Goff BA, Sainz de la Cuesta R, Muntz HG et al, Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60: 412-417.
4. Czernobilsky 8, Silverman BE, Enterline HT. Clear-cell carcinoma of the ovary. A clinicopathologic analysis of pure and mixed forms and comparison with endometrioid carcinoma. Cancer 1970; 25: 762-772.
5. Matsuura Y, Robertson G, Marsden DE et al. Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 2007; 104: 406-410.
6. Mizuno M, Kikkawa F, Shibata K et al. Long-term prognosis of stage I ovarian carcinoma, Prognostic importance of intraoperative rupture. Oncology 2003; 65: 20-36.
7. Takano M, Kikuchi Y, Yaegashi N et al. Clear cell carcinoma of the ovary: A retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006; 94: 1369-1374.
8. Kennedy AW, Markman M, Biscotti CV et al. Survival probability in ovarian clear cell adenocarcinoma. Gynecol Oncol 1999; 74: 108-114.
9. O'Brien ME, Schofield JB, Tan S et al. Clear cell epithelial ovarian cancer (mesonéphroid): Bad prognosis only in early stages. Gynecol Oncol 1993; 49: 250-254.
10. Jenison EL, Montag AG, Griffiths CT et al. Clear cell adenocarcinoma of the ovary: A clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989; 32: 65-71.
11. Ho CM, Chien TY, Shih BY et al. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol 2003; 88: 394-399.
12. Chan JK, Munro EG, Cheung MK et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 2007; 109: 12-19.